GreenLight Clinical team is established and run by a group of highly-regarded physicians and researchers with a multi-disciplinary skill set, and a proven track record in delivering high quality research output to our clients.
Our staff of experienced, knowledgeable clinical trial professionals aims to provide the highest quality research outcomes for our partners, and as a full-service provider, our teams cover all aspects of clinical trial management, drug & device development and global regulatory affairs.
PRESIDENT & CEO
Dr. Sasi Suda – MD, PhD (USyd)
Dr Sasi Suda is the Chief Executive Officer at GreenLight Clinical.
Dr. Suda is qualified as a medical practitioner in Australia and has extensive experience in the pharmaceutical industry and clinical research as both a researcher and clinical trial professional.
Clinical Associate Professor
Andrew Chang – MBBS(Hons), PhD (USyd), FRANZCO, FRACS
Associate Professor Andrew Chang is a vitreoretinal surgeon and ophthalmologist. He holds an academic appointment of Clinical Associate Professor at the University of Sydney.
MANAGEMENT AND MEDICAL TEAM
Global People and Culture Director – Tracy Mellor
Tracy has over 20 years experience in the Pharmaceutical industry in Business Development, Training, Leadership Development and People and Culture in BMS, Kabi Pharmacia Farmitalia Upjohn and Novo Nordisk in Europe and Australia.
She has proven successful Business Leadership experience in several global roles and understands the challenges and benefits of working in Australia for a global company.
Group General Counsel, Compliance & Risk – Franz D’Lima
Franz D’Lima has over 20 years experience as a senior corporate lawyer and general counsel in global FMCG, healthcare and B2B industries. His diverse experience in ANZ, EMEA, and APAC (including emerging markets such as China and India), has helped him develop an acute understanding of the legal environment in multiple jurisdictions as well as an appreciation of cross-cultural sensitivities.
Franz approaches legal issues from a commercial perspective and has acquired a reputation as a trusted business partner. He has managed a number of complex projects including the successful transition of a US$100M healthcare business in Japan, the divestment of multi-million dollar cigarette paper businesses in Indonesia and the Philippines and established manufacturing facilities and R&D centres across the Asia Pacific region.
Quality Assurance, Regulatory Affairs and Pharmacovigilance Director – Peter Yeates
Peter has worked with biologicals, medicines, medical devices and health practitioners in the research setting, hospitals and industry for over 35 years and has developed a strong understanding of the product development continuum including reimbursement and post-marketing requirements.
Previous management and director roles in the medical industry (Alcon, AstraZeneca, Pfizer, Janssen Cilag and Wyeth) included Compliance, Medical affairs, Medical information, Medical safety, Regulatory affairs, Reimbursement and Quality. Peter has a reputation for successfully managing difficult projects.
Chief Scientific Officer – Tailoi Chan-Ling
PhD, FAAO, FARVO
A distinguished academic career and tertiary leader spanning over 28 years, with expertise in ocular cell biology, neurobiology, stem cell biology, angiogenesis, nanotechnology, ophthalmology and optometry. Extensive portfolio of high impact peer-reviewed publications and conference presentations, including co-authorship of the Nature classic on Angiogenesis, identifying VEGF as the angiogenic growth factor as the key driver of normal ‘physiological’ angiogenesis in the CNS and retina.
A track record of contribution to ocular biology/pathology spanning the cornea to the posterior eye including the optic nerve with relevance to glaucoma, diabetic retinopathy and edema, age-related macular degeneration, Retinopathy of Prematurity and corneal function. Total citations over 7500, h index = 48.